These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 38539518)

  • 41. Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial.
    Radovich M; Jiang G; Hancock BA; Chitambar C; Nanda R; Falkson C; Lynce FC; Gallagher C; Isaacs C; Blaya M; Paplomata E; Walling R; Daily K; Mahtani R; Thompson MA; Graham R; Cooper ME; Pavlick DC; Albacker LA; Gregg J; Solzak JP; Chen YH; Bales CL; Cantor E; Shen F; Storniolo AMV; Badve S; Ballinger TJ; Chang CL; Zhong Y; Savran C; Miller KD; Schneider BP
    JAMA Oncol; 2020 Sep; 6(9):1410-1415. PubMed ID: 32644110
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Monitoring Treatment Response, Early Recurrence, and Survival in Uterine Serous Carcinoma and Carcinosarcoma Patients Using Personalized Circulating Tumor DNA Biomarkers.
    Bellone S; McNamara B; Mutlu L; Demirkiran C; Hartwich TMP; Harold J; Yang-Hartwich Y; Siegel ER; Santin AD
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240216
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.
    Vandekerkhove G; Struss WJ; Annala M; Kallio HML; Khalaf D; Warner EW; Herberts C; Ritch E; Beja K; Loktionova Y; Hurtado-Coll A; Fazli L; So A; Black PC; Nykter M; Tammela T; Chi KN; Gleave ME; Wyatt AW
    Eur Urol; 2019 Apr; 75(4):667-675. PubMed ID: 30638634
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.
    Wyatt AW; Annala M; Aggarwal R; Beja K; Feng F; Youngren J; Foye A; Lloyd P; Nykter M; Beer TM; Alumkal JJ; Thomas GV; Reiter RE; Rettig MB; Evans CP; Gao AC; Chi KN; Small EJ; Gleave ME
    J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 29206995
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Natural History of Germline BRCA1 Mutated and BRCA Wild-type Triple-negative Breast Cancer.
    Gardi N; Chaubal R; Parab P; Pachakar S; Kulkarni S; Shet T; Joshi S; Kembhavi Y; Chandrani P; Quist J; Kowtal P; Grigoriadis A; Sarin R; Govindarajan R; Gupta S
    Cancer Res Commun; 2024 Feb; 4(2):404-417. PubMed ID: 38315150
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Next-generation sequencing of circulating tumor DNA for detection of gene mutations in lung cancer: implications for precision treatment.
    Lai J; Du B; Wang Y; Wu R; Yu Z
    Onco Targets Ther; 2018; 11():9111-9116. PubMed ID: 30588023
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Plasma ctDNA increases tissue NGS-based detection of therapeutically targetable mutations in lung cancers.
    Xie J; Yao W; Chen L; Zhu W; Liu Q; Geng G; Fang J; Zhao Y; Xiao L; Huang Z; Zhao J
    BMC Cancer; 2023 Mar; 23(1):294. PubMed ID: 37004022
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical spectrum and prognostic value of TP53 mutations in circulating tumor DNA from breast cancer patients in China.
    Yi Z; Ma F; Rong G; Guan Y; Li C; Xu B
    Cancer Commun (Lond); 2020 Jun; 40(6):260-269. PubMed ID: 32436611
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Postoperative Circulating Tumor DNA Can Predict High Risk Patients with Colorectal Cancer Based on Next-Generation Sequencing.
    Lee CS; Kim HS; Schageman J; Lee IK; Kim M; Kim Y
    Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439344
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Detection of TP53/PIK3CA Mutations in Cell-Free Plasma DNA From Metastatic Breast Cancer Patients Using Next Generation Sequencing.
    Nakauchi C; Kagara N; Shimazu K; Shimomura A; Naoi Y; Shimoda M; Kim SJ; Noguchi S
    Clin Breast Cancer; 2016 Oct; 16(5):418-423. PubMed ID: 27265061
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comprehensive Genomic Analysis of Patients With Non-Small-Cell Lung Cancer Using Blood-Based Circulating Tumor DNA Assay: Findings From the BFAST Database of a Single Center in Taiwan.
    Wang HY; Ho CC; Lin YT; Liao WY; Chen CY; Shih JY; Yu CJ
    JCO Precis Oncol; 2024 Jan; 8():e2300314. PubMed ID: 38190582
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Potential Management of Circulating Tumor DNA as a Biomarker in Triple-Negative Breast Cancer.
    Shang M; Chang C; Pei Y; Guan Y; Chang J; Li H
    J Cancer; 2018; 9(24):4627-4634. PubMed ID: 30588246
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Somatic mutation detection using various targeted detection assays in paired samples of circulating tumor DNA, primary tumor and metastases from patients undergoing resection of colorectal liver metastases.
    Beije N; Helmijr JC; Weerts MJA; Beaufort CM; Wiggin M; Marziali A; Verhoef C; Sleijfer S; Jansen MPHM; Martens JWM
    Mol Oncol; 2016 Dec; 10(10):1575-1584. PubMed ID: 28949453
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Detection of circulating tumor DNA from non-small cell lung cancer brain metastasis in cerebrospinal fluid samples.
    Ma C; Yang X; Xing W; Yu H; Si T; Guo Z
    Thorac Cancer; 2020 Mar; 11(3):588-593. PubMed ID: 31944608
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Survival Implications of the Relationship between Tissue versus Circulating Tumor DNA
    Rosenberg S; Okamura R; Kato S; Soussi T; Kurzrock R
    Mol Cancer Ther; 2020 Dec; 19(12):2612-2620. PubMed ID: 32999047
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Circulating Tumor DNA as a Novel Biomarker Optimizing Treatment for Triple Negative Breast Cancer.
    Sun Y; Zhu C; Xu F; Cui S; Guan X
    Clin Breast Cancer; 2023 Jun; 23(4):339-349. PubMed ID: 36966079
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Blood-based genomics of triple-negative breast cancer progression in patients treated with neoadjuvant chemotherapy.
    Ortolan E; Appierto V; Silvestri M; Miceli R; Veneroni S; Folli S; Pruneri G; Vingiani A; Belfiore A; Cappelletti V; Vismara M; Dell'Angelo F; De Cecco L; Bianchi GV; de Braud FG; Daidone MG; Di Cosimo S
    ESMO Open; 2021 Apr; 6(2):100086. PubMed ID: 33743331
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Monitoring treatment efficacy and resistance in breast cancer patients via circulating tumor DNA genomic profiling.
    Chen Z; Sun T; Yang Z; Zheng Y; Yu R; Wu X; Yan J; Shao YW; Shao X; Cao W; Wang X
    Mol Genet Genomic Med; 2020 Feb; 8(2):e1079. PubMed ID: 31867841
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Circulating Tumor DNA as a Predictive Marker of Recurrence for Patients With Stage II-III Breast Cancer Treated With Neoadjuvant Therapy.
    Lin PH; Wang MY; Lo C; Tsai LW; Yen TC; Huang TY; Huang WC; Yang K; Chen CK; Fan SC; Kuo SH; Huang CS
    Front Oncol; 2021; 11():736769. PubMed ID: 34868925
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Baseline circulating tumor DNA predicts long-term survival outcomes for patients with early breast cancer.
    Zhang X; Feng R; Xu Y; Yang L; Xie F; Yang H; Wang S; Peng Y; Liu M; Wang C; Wang S
    Gland Surg; 2024 May; 13(5):684-696. PubMed ID: 38845832
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.